Wudang pharmaceutical company among top 50 in TCM research and development

Guiyang Xintian Pharmaceutical Co (Xintian Pharmaceutical) was recently named among the top 50 in the Research and Development (R&D) of Traditional Chinese Medicine (TCM) for 2024, as revealed at the 2024 International Pharmaceutical Service Industry Innovation and Development Conference and the 9th China Pharmaceutical R&D Innovation Summit held in early July.

Located in Wudang district, Guiyang, capital of Southwest China's Guizhou province, Xintian Pharmaceutical is the only TCM enterprise from Guizhou to make the list this year.

As a national high-tech enterprise with nearly 30 years of experience in modern TCM, Xintian Pharmaceutical has developed leading proprietary patent varieties and products listed in the national medical insurance directory, such as Kuntai Capsules, Ningmitai Capsules, Kushen Gel, and Xiakucao Oral Liquid.

The company has established a "two-three-four" R&D layout: two provinces/cities – Guizhou province and Shanghai city, three bases – Guiyang Xintian Pharmaceutical, Shanghai Shuofang Pharmaceutical, and Shanghai Haitian Pharmaceutical, and four modules – innovative research on new TCM, pharmaceutical research on new TCM, industrial transformation and technical improvement of new TCM, and post-market clinical evaluation of new TCM.

This year, Xintian Pharmaceutical's affiliated company, Shanghai Huilun Pharmaceutical Co was named among the Top 100 in the R&D of Chemical Drugs for 2024. Both companies share the same founder and owner.